Catalog No.
Product Name
Application
Product Information
Citations
-
Wee1 Inhibitor
PKMYT1-IN-4 is a potent PKMYT1 inhibitor with an IC50 of less than 50 nM. This compound selectively targets the Wee1 kinase, a critical regulator of the cell cycle. PKMYT1-IN-4 is utilized in research applications focused on cell cycle regulation and cancer biology, making it suitable for studies exploring therapeutic strategies against proliferative diseases. -
MYT1 Kinase Inhibitor
Myt1-IN-6 is a selective inhibitor of MYT1 kinase, which plays a crucial role in the regulation of cell cycle progression and neuronal differentiation. This compound is particularly relevant for studies involving RB1-deficient cancers, such as triple-negative breast cancer, where MYT1 activity may contribute to oncogenesis and tumor progression. Myt1-IN-6 serves as a valuable tool for exploring therapeutic strategies targeting MYT1 in various malignancies. -
G-quadruplex Inhibitor
Phen-DC3 Trifluoromethanesulfonate is a specific ligand that targets G-quadruplex (G4) structures, effectively inhibiting the helicases FANCJ and DinG with IC50 values of 65±6 nM and 50±10 nM, respectively. This compound plays a critical role in research focused on telomere biology, DNA replication, and cancer therapeutics. Its ability to modulate G4 structures makes it a valuable tool for investigating G4-associated cellular processes and the development of novel anti-cancer strategies. -
G-quadruplex Ligand
Carboxy pyridostatin trifluoroacetate salt is a G-quadruplex ligand that selectively interacts with G-quadruplex structures in RNA and DNA. This compound has been shown to decrease levels of ATF-5 protein, thereby inhibiting cell proliferation and disrupting stress granule formation. It serves as a valuable tool in the study of G-quadruplex biology and its implications in cellular stress responses and cancer research. -
G-quadruplex Stabilizer
BMVC2 is a bisubstituted carbazole derivative that serves as a G-quadruplex (G4) stabilizer. This compound promotes the formation and stabilization of G-quadruplex structures, which are important in the regulation of gene expression and telomere maintenance. BMVC2 is utilized in research applications focusing on cancer biology, antiviral therapies, and the development of novel molecular therapeutics targeting G4 DNA structures. -
G-quadruplex Ligand
Carboxypyridostatin is a selective ligand for G-quadruplex structures. It demonstrates significant affinity for RNA G-quadruplexes, leading to the downregulation of ATF-5 protein levels. This compound is known to inhibit cell proliferation and interfere with stress granule formation, making it valuable for studies on cellular stress responses and G-quadruplex-related mechanisms in cancer research. -
G-quadruplexes Stabilizer
Pyridostatin trihydrochloride is a potent G-quadruplex stabilizer with a binding affinity (Kd) of 490 nM, effectively targeting DNA and RNA G-quadruplex structures within cellular environments. This compound induces growth arrest in human cancer cells through mechanisms involving replication- and transcription-dependent DNA damage. Pyridostatin specifically impacts the proto-oncogene Src, leading to diminished SRC protein levels and reduced SRC-dependent cellular motility in human breast cancer cells. Its applications extend to cancer research, particularly in studying mechanisms of tumor progression and drug resistance. -
G-quadruplex
Nemorubicin hydrochloride is a doxorubicin derivative that primarily targets G-quadruplex structures. It exhibits notable antitumor activity by intercalating into duplex DNA while also serving as a potent ligand for G-quadruplex DNA segments, effectively stabilizing their conformation. This compound is valuable for research applications focused on understanding G-quadruplex biology and developing therapeutic strategies targeting this unique DNA structure. -
LIMK Inhibitor
CRT0105950 is a potent LIMK inhibitor, selectively targeting LIMK1 and LIMK2 with IC50 values of 0.3 nM and 1 nM, respectively. Its primary mechanism involves the inhibition of LIM kinases, which play a crucial role in regulating actin cytoskeleton dynamics and cell motility. This reagent is valuable for investigating tumor biology and potential therapeutic pathways in cancer research. -
LIMK1 Inhibitor
SR7826 is a potent and selective LIMK1 inhibitor, exhibiting an IC50 of 43 nM. This bis-aryl urea derivative demonstrates over 100-fold selectivity for LIMK1 compared to ROCK and JNK kinases. SR7826 serves as a valuable tool for investigating LIMK1-related signaling pathways and its role in cellular processes such as cytoskeletal dynamics and cancer progression. -
LIMK1/2 Inhibitor
TH470 is a highly selective inhibitor of LIMK1 and LIMK2, exhibiting IC50 values of 9.8 nM and 13 nM, respectively. This compound effectively modulates the actin cytoskeleton and related cellular processes by inhibiting LIM kinase activity. TH470 is particularly valuable in the study of orphan diseases and other conditions related to dysregulated LIMK signaling. -
LIMK Inhibitor
LIMK1 inhibitor BMS-4 is a selective inhibitor of LIM Kinases (LIMK1 and LIMK2). By inhibiting LIMK1, BMS-4 effectively blocks the phosphorylation of cofilin, a critical substrate, thereby modulating actin dynamics. It has demonstrated noncytotoxicity in A549 cells, making it a valuable tool for investigating LIMK-related pathways and their roles in cancer cell migration and invasion. -
LIM Kinase (LIMK) Inhibitor
MDI-114215 is an allosteric inhibitor targeting LIM Kinase 1 and 2 (LIMK1/2). It effectively inhibits the phosphorylation of cofilin in induced pluripotent stem cells (iPSCs) derived from mouse brain regions. This compound shows potential applications in research related to Fragile X Syndrome (FXS), enabling investigations into cellular pathways affected by LIMK activity. -
LIMK1 Inhibitor
LIMK1 inhibitor 2 is a selective inhibitor of LIM kinase 1 (LIMK1), demonstrating an IC50 value of 9 μM. This compound effectively blocks LIMK1 activity, leading to the modulation of cytoskeletal dynamics. It is primarily utilized in research to investigate cellular processes such as cell migration, proliferation, and differentiation, contributing valuable insights into cancer biology and other related fields. -
LIMK1 Inhibitor
8β,9α-Dihydroxylindan-4(5),7(11)-dien-8alpha,12-olide is a sesquiterpene that acts as a selective inhibitor of LIMK1. By targeting this kinase, the compound effectively modulates cell motility, making it valuable for studies investigating cytoskeletal dynamics and cell migration. This reagent is applicable in various research contexts, including cancer metastasis and neurobiology, where LIMK1 plays a critical role. -
LIMK2 Inhibitor
LIMK-IN-3 is a potent inhibitor of LIMK2, demonstrating an IC50 of 1.2 nM. This compound exhibits significant inhibition of LIMK2 activity, which is crucial for understanding the role of LIMK2 in various cellular processes. LIMK-IN-3 is particularly relevant in glaucoma research, providing valuable insights into the molecular mechanisms underlying this condition. -
LIMK Inhibitor
LIJTF500025 is a potent and selective LIMK inhibitor that targets LIMK1 and LIMK2, exhibiting pIC50 values of 6.77 and 7.03, respectively, as determined by NanoBRET. This compound plays a crucial role in modulating actin dynamics and has potential applications in cancer research. Its ability to inhibit LIM kinase activity makes it a valuable tool for investigating the mechanisms underlying tumor progression and metastasis. -
LIMK1 Inhibitor
CRT 0105446 is a selective inhibitor of LIMK1, exhibiting an IC50 value of 8 nM. This compound is valuable for investigating the role of LIMK1 in cellular processes such as cytoskeletal dynamics and cell migration. Researchers can utilize CRT 0105446 to explore its effects in studies related to cancer, neurodegenerative diseases, and other conditions where LIMK1 modulation is implicated. -
LIM1 Inhibitor
Curcolonol is a furan-type sesquiterpene that acts as an inhibitor of LIM kinase 1. It exhibits significant inhibitory activity against this target, making it a valuable compound for studying pathways involved in cancer progression. Curcolonol is particularly relevant for research applications in breast cancer, providing insights into potential therapeutic mechanisms and treatment strategies. -
LIMK Inhibitor
LIMK-IN-2 is a selective LIMK inhibitor that exhibits significant capacity to inhibit cell migration in osteosarcoma and cervical cancer cells. This compound demonstrates potential anti-angiogenic activity, making it a valuable tool for investigating the role of LIMK in cancer progression and therapeutic strategies. Research applications include studies focused on metastasis and the regulation of cellular motility in tumor biology. -
LIMK1 Inhibitor
LIMK1 Inhibitor 1 is a selective inhibitor of LIM domain kinase 1 (LIMK1), a critical regulator of actin cytoskeletal dynamics. This compound demonstrates potential anti-cancer activity by disrupting cancer cell migration and invasion. LIMK1 Inhibitor 1 is applicable in research focused on understanding the role of LIMK1 in oncogenesis and exploring therapeutic strategies for cancer treatment. -
PLK-1/Tubulin Inhibitor
3,4,3'-Tri-O-methylflavellagic acid is a flavonoid compound that functions as an inhibitor of polo-like kinase-1 (PLK-1) and αβ-tubulin at the colchicine binding site. This compound disrupts microtubule assembly dynamics and modulates kinase activity, making it valuable for research into cancer cell proliferation and anti-nociceptive properties. Its unique biological activities make it a significant reagent for studies focused on cancer therapies and pain management. -
TTK/PLK1 Inhibitor
TTK/PLK1-IN-1 is a potent inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1), demonstrating IC50 values of 7 nM and 72 nM, respectively. This compound plays a crucial role in regulating the spindle assembly checkpoint (SAC), making it relevant for cancer research. It exhibits promising antitumor activity against triple-negative breast cancer (TNBC), contributing to its potential applications in oncology studies. -
PLK1 Inhibitor
GSK461364 analogue 1 is a thiophene-based inhibitor targeting Polo-like kinase 1 (PLK1), exhibiting an IC50 value of 2 nM, along with inhibitory activity against PLK3 (IC50: 630 nM) and Nek2 kinase (IC50: 21 nM). With a solubility of ≥190 μM in pH 7.4 PBS and a human plasma protein binding rate of 91.5%, this compound is suitable for in vitro studies. GSK461364 analogue 1 is particularly relevant for research into malignancies such as colon, lung, breast, and ovarian cancers. -
KRAS G12C Inhibitor
KRAS G12C inhibitor 27 is a potent inhibitor targeting the KRAS G12C mutant protein, which plays a pivotal role in various cancers. This compound exhibits significant antitumor activity, making it a valuable tool for research in cancer biology and therapeutic development. Its application extends to studying KRAS-driven tumors and evaluating the efficacy of targeted therapies. -
KRAS G12D Inhibitor
KRAS G12D inhibitor 3 is a selective inhibitor targeting the KRAS G12D mutant with an IC50 of less than 500 nM. It exhibits significant antitumor activity, making it relevant for cancer research focused on KRAS-driven tumors. Additionally, this compound functions as a click chemistry reagent, featuring an alkyne group that enables copper-catalyzed azide-alkyne cycloaddition with azide-containing molecules, facilitating various bioconjugation applications in molecular biology. -
G12Si-1 Analog
G12Si-2 is an analog of G12Si-1 that serves as a negative control in research applications. It acts as a non-covalent inhibitor specifically for the G12S mutant of K-Ras. This compound is valuable for studies aimed at elucidating the mechanisms of K-Ras signaling and evaluating the effects of various inhibitors in cellular contexts. -
KRAS G12C Inhibitor
KRAS G12C-IN-74 is a selective inhibitor of KRAS G12C with a target IC50 of 43.18 nM. This compound induces G0/G1 cell cycle arrest and promotes apoptosis specifically in KRAS G12C-mutated cancer cells. It is suitable for research applications focusing on KRAS G12C-driven pancreatic, colorectal, and lung cancers. -
cAMP Analogue
8-CPT-cAMP-AM is a membrane-permeant analogue of cyclic adenosine monophosphate (cAMP) that acts as an activator of cAMP- and cGMP-dependent protein kinases. It also stimulates exchange protein directly activated by cAMP (Epac), making it a valuable tool for investigating cAMP signaling pathways. This compound is useful in research applications studying cellular processes influenced by cAMP, such as cell proliferation, differentiation, and effects on various physiological responses. -
pan-KRAS Inhibitor
pan-KRAS-IN-6 is a highly potent pan-KRAS inhibitor, exhibiting IC50 values of 9.79 nM for Kras G12D and 6.03 nM for Kras G12V. This compound effectively targets KRAS mutant forms associated with various cancers, making it a valuable tool for studying KRAS signaling pathways and evaluating therapeutic strategies in KRAS-driven tumors. Its specificity and efficacy position it as a key reagent in cancer research and drug discovery efforts targeting KRAS-related malignancies. -
KRAS G12C inhibitor
KRAS G12C inhibitor 21 is a selective inhibitor targeting the KRAS G12C oncogene. It effectively disrupts downstream signaling pathways associated with cell proliferation and survival in KRAS-driven malignancies. This compound is primarily utilized in cancer research to explore therapeutic strategies for malignancies harboring KRAS G12C mutations. -
Anti-cancer Agent
KRAS G12C inhibitor 37 is a selective inhibitor targeting the KRAS G12C mutation, a key driver in various cancers. This compound displays significant efficacy in disrupting KRAS-mediated signaling pathways, thus impeding tumor growth and proliferation. KRAS G12C inhibitor 37 is intended for research applications focused on elucidating the therapeutic potential in KRAS G12C-driven malignancies. -
pan-KRAS Inhibitor
pan-KRAS-IN-15 is a pan-KRAS inhibitor that targets multiple KRAS mutant variants. This compound exhibits potent inhibitory activity against KRAS-driven signaling pathways, making it valuable for studying the mechanisms of KRAS-related cancers. It is particularly relevant for research focused on pancreatic cancer, providing insights into therapeutic strategies and disease progression. -
KRAS Inhibitor
KRAS Inhibitor-22 is a selective inhibitor of the K-Ras protein, specifically targeting the Kras 4B(G12D) and Kras 4B(G12C) mutant forms. This compound exhibits potent anti-cancer activity, making it a valuable tool in cancer research aimed at understanding K-Ras-driven malignancies. Its application can aid in elucidating the role of K-Ras in cancer progression and therapeutic resistance. -
KRAS G12C Inhibitor
KRAS inhibitor-13 is a selective inhibitor targeting the mutant KRAS G12C protein, demonstrating its potency with an IC50 value of 0.883 µM. This compound effectively inhibits phosphorylated ERK (p-ERK) in cell lines, showing IC50s of 5.9 µM in MIA PaCA-2 cells and >100 µM in A549 cells. KRAS inhibitor-13 is poised for research applications focused on pancreatic, colorectal, and lung cancers, providing insights into therapeutic strategies against KRAS-driven malignancies. -
KRAS G12C Inhibitor
KRAS G12C Inhibitor 44 is a potent and orally bioavailable inhibitor targeting the KRAS G12C mutation. This compound exhibits significant anti-proliferative activity, with IC50 values of 0.016 µM in MIA PaCA-2 cells and 0.028 µM in H358 cells. Additionally, KRAS G12C Inhibitor 44 demonstrates antitumor effects in vivo, making it a valuable tool for cancer research focusing on KRAS-driven malignancies. -
KRAS G12C Inhibitor
KRAS G12C inhibitor 52 is a selective inhibitor targeting the KRAS G12C mutant protein. This compound effectively disrupts KRAS signaling pathways, thereby inhibiting cell proliferation and survival in KRAS G12C-driven cancers. Its research applications include studies on cancer biology, drug development, and understanding resistance mechanisms in targeted therapies. -
KRAS G12C Inhibitor
KRAS inhibitor-12 is a potent inhibitor specifically targeting the KRAS G12C mutation, exhibiting an IC50 of 0.537 µM. This compound demonstrates effective inhibition of phosphorylated ERK in MIA PaCA-2 and A549 cells, with IC50 values of 1.3 µM and 3.7 µM, respectively. KRAS inhibitor-12 is a valuable tool for investigating therapeutic strategies in pancreatic, colorectal, and lung cancers. -
Anti-cancer Agent
KRAS G12D inhibitor 12 specifically targets the KRAS G12D mutation, a critical player in cellular signaling pathways associated with tumorigenesis. This compound exhibits potent anti-cancer activity, making it a valuable tool for researchers investigating KRAS G12D-mediated cancers. Its application includes evaluating therapeutic strategies and understanding the molecular mechanisms of oncogenic signaling in various cancer types. -
KRAS G12C Inhibitor
KRAS G12C Inhibitor 46 is a potent inhibitor targeting the KRAS G12C mutation, an essential driver in various cancers. This compound effectively blocks the aberrant signaling pathways associated with KRAS G12C, leading to reduced proliferation and enhanced apoptosis in cancer cells harboring this mutation. It is primarily utilized in cancer research, particularly for exploring therapeutic strategies targeting KRAS-dependent tumors. -
KRAS Inhibitor
KRAS Inhibitor-23 is a selective inhibitor targeting KRAS, a critical protein involved in cell signaling pathways that regulate cell growth and differentiation. This compound demonstrates significant biological activity by effectively disrupting KRAS-mediated oncogenic signaling, making it a valuable tool in cancer research. Its application spans the investigation of KRAS mutations and their role in tumor progression, providing insights into potential therapeutic strategies for KRAS-driven malignancies. -
KRASG12D Inhibitor
KRASG12D-IN-5 is a potent inhibitor targeting the KRAS(G12D) mutation, exhibiting an IC50 of 11 nM. This compound demonstrates significant anticancer activity, displaying low cytotoxicity against various cell lines, including 10.37 μM for BxPC-3 (wild type), 0.76 μM for KRAS mutant AsPC-1 (G12D), and 0.3 μM for MIAPaCa-2 (G12C). KRASG12D-IN-5 is valuable for cancer research, particularly in the context of lung, pancreatic, and colorectal cancers. -
Mutant KRAS Inhibitor
KRAS-IN-48 free base is a highly selective inhibitor targeting mutant KRAS, specifically KRAS G12D and KRAS G12V, with Kd values of 2.58 nM and 5.49 μM, respectively. This compound effectively reduces pERK expression in KRAS-mutant cells, exhibiting IC50 values of 1.1 μM and 1.51 μM for KRAS G12D and G12V mutations. KRAS-IN-48 free base serves as a valuable tool in cancer research, contributing to the understanding of KRAS-driven malignancies. -
KRAS G12D Inhibitor
KRAS G12D inhibitor 24 is a potent inhibitor of the KRAS G12D mutant, exhibiting an IC50 of 0.004 μM. This compound demonstrates significant oral bioactivity, making it suitable for in vivo studies. Its primary applications include exploring therapeutic avenues in cancer research, specifically for tumors driven by KRAS G12D mutations. -
KRAS G12C Inhibitor
KRAS G12C inhibitor 58 specifically targets the KRAS G12C mutant protein, effectively disrupting its activity and downstream signaling pathways. This compound demonstrates potent antitumor efficacy, making it a valuable tool for studying KRAS-driven malignancies. Its applications extend to cancer research, particularly in the development and testing of novel therapeutic strategies for treating KRAS G12C-dependent tumors. -
KRAS Inhibitor
pan-KRAS-IN-13 is a potent KRAS inhibitor that targets mutant forms of the KRAS protein, demonstrating IC50 values of 2.75 nM and 2.89 nM for G12D and G12V mutations, respectively. This compound is valuable for research applications aimed at understanding KRAS-driven cancers and evaluating therapeutic strategies to inhibit KRAS signaling pathways. Its high specificity and efficacy make it a critical tool for the study of oncogenic mutations associated with various malignancies. -
KRAS G12D Inhibitor
RNK08954 is a KRAS G12D inhibitor targeting the KRAS oncogene mutation commonly found in various cancers. This compound demonstrates the ability to impede KRAS-driven cellular signaling pathways, making it a valuable tool for investigating the role of KRAS G12D in tumorigenesis. RNK08954 is suitable for research applications focused on cancer biology and therapeutic development against KRAS-mutant tumors. -
cAMP Analogue
8-Br-2'-O-Me-cAMP is a synthetic analog of cyclic AMP (cAMP) that selectively activates exchange factors activated by cAMP (Epac) without stimulating protein kinase A (PKA). This unique property makes it a valuable tool for investigating cAMP-mediated signaling pathways. It is particularly relevant in studies related to cardiovascular diseases, facilitating the exploration of Epac's role in cardiac function and pathology. -
Anti-cancer Agent
KRAS G12C inhibitor 40 is a selective inhibitor targeting the KRAS G12C mutation, a critical driver in various cancers. This compound disrupts the aberrant signaling pathways associated with KRAS G12C, demonstrating significant anti-cancer activity. KRAS G12C inhibitor 40 is valuable for research into the mechanisms of KRAS G12C-mediated tumorigenesis and for the development of targeted cancer therapies. -
KRAS G12C Inhibitor
ARS-2102 is a potent covalent inhibitor of the KRAS G12C mutation, a key driver in various cancers. By selectively targeting this mutated oncogene, ARS-2102 exhibits significant anti-tumor activity, making it a valuable tool for cancer research. Its application is particularly relevant in studies focused on therapeutic strategies for KRAS-driven malignancies.
